<DOC>
	<DOCNO>NCT01769378</DOCNO>
	<brief_summary>The purpose study assess efficacy safety once-weekly dulaglutide compare placebo participant type 2 diabetes inadequate glycemic control sulfonylurea monotherapy .</brief_summary>
	<brief_title>Study How Dulaglutide Compares Placebo Participants With Type 2 Diabetes Who Are Also Sulfonylurea Therapy ( AWARD-8 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes mellitus Stable dose sulfonylurea least 50 % maximum approve dose per local label least 3 month prior first study visit Have HbA1c value ≥7.5 % ≤9.5 % , determined central laboratory draw perform first study visit Accept continue treatment sulfonylurea therapy , throughout trial , require per protocol Men nonpregnant woman age ≥18 year Stable weight ( ±5 % ) ≥3 month prior screen Body Mass Index ( BMI ) ≤45 kilogram per square meter ( kg/m^2 ) Have type 1 diabetes mellitus Have treat ANY antihyperglycemic medication ( sulfonylurea ) time first study visit within 3 month prior first study visit Have use insulin therapy ( outside pregnancy ) time past 2 year , except shortterm treatment acute condition , maximum 4 week ; insulin within 3 month prior first study visit exclusionary Have treat drug promote weight loss within 3 month prior first study visit Are receive chronic ( &gt; 14 day ) systemic glucocorticoid therapy receive therapy within 4 week immediately prior first study visit Have follow Cardiovascular ( CV ) condition within 2 month prior first study visit : acute myocardial infarction , New York Heart Association Class III Class IV heart failure , cerebrovascular accident Have know clinically significant gastric empty abnormality ( eg , severe diabetic gastroparesis gastric outlet obstruction ) undergone gastric bypass ( bariatric ) surgery restrictive bariatric surgery Have acute chronic hepatitis , sign symptoms liver disease , alanine transaminase level &gt; 2.5 time upper limit normal Have history chronic pancreatitis acute idiopathic pancreatitis , diagnose type acute pancreatitis within 3 month period prior first study visit Have estimate glomerular filtration rate [ eGFR ] &lt; 30 milliliter per minute per 1.73 square meter ( mL/min/1.73 m^2 ) , calculate use Chronic Kidney Disease Epidemiology Collaboration [ CKDEPI ] equation determine central laboratory first study visit Have self family history type 2A type 2B multiple endocrine neoplasia ( MEN 2A 2B ) absence know Ccell hyperplasia ( exclusion include participant family history MEN 2A 2B , whose family history syndrome Rearranged Transfection ( RET ) negative ; exception exclusion participant whose family member MEN 2A 2B know RET mutation potential participant study negative RET mutation ) Have self family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma ( include sporadic , familial part MEN 2A 2B syndrome ) Have serum calcitonin ≥20 picogram per milliliter ( pg/mL ) determine central laboratory first study visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>